Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | HMGCR | P04035 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CPT2 | P23786 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 3/20 | 0.33 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL416276 | 1.00 | CYP2C19 (0.50) | CYP2C19HIF1ATSHRCYP2D6HMGCR | |
| SCHEMBL3713463 | 1.00 | CYP2C19 (0.50) | CYP2C19HIF1ATSHRCYP2D6HMGCR | |
| SCHEMBL28838440 | 0.83 | CYP2D6 (0.36) | CYP2C19HIF1ATSHRCYP2D6HMGCR | |
| SCHEMBL13688692 | 0.83 | HMGCR (0.44) | CYP2C19HIF1ATSHRCYP2D6HMGCR | |
| SCHEMBL11180724 | 0.81 | HMGCR (0.42) | CYP2C19HIF1ATSHRCYP2D6HMGCR | |
| SCHEMBL19031719 | 0.78 | CYP2C19 (0.48) | CYP2C19HIF1ATSHRCYP2D6HMGCR | |
| SCHEMBL18138374 | 0.78 | CYP2C19 (0.43) | CYP2C19HIF1ATSHRCYP2D6HMGCR | |
| SCHEMBL823261 | 0.77 | — | — | |
| SCHEMBL535726 | 0.77 | — | — | |
| SCHEMBL7200959 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558597-B1 | CONTINUOUS PROCESS FOR THE PRODUCTION OF OPTICALLY PURE (S)-BETA HYDROXY-GAMMA-BUTYROLACTONE | SK HOLDINGS CO LTD (KR) | 2008-05-07 | — | — | EP | disclosed |
| US-20070093660-A1 | Method for the production of statins | RATIOPHARM GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| EP-1558597-A4 | CONTINUOUS PROCESS FOR THE PRODUCTION OF OPTICALLY PURE (S)-BETA HYDROXY-GAMMA-BUTYROLACTONE | SK CORP (KR) | 2006-06-07 | — | — | EP | disclosed |
| US-20060052617-A1 | Continuous process for the production of optically pure (s)-beta-hydroxy-y-butyrolactone | SK CORPORATION | 2006-03-09 | — | — | US | disclosed |
| EP-1558597-A2 | CONTINUOUS PROCESS FOR THE PRODUCTION OF OPTICALLY PURE (S)-BETA HYDROXY-GAMMA-BUTYROLACTONE | SK Corporation (KR) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004026223-A2 | CONTINUOUS PROCESS FOR THE PRODUCTION OF OPTICALLY PURE (S)-β HYDROXY-Ϝ-BUTYROLACTONE | SK CORPORATION (KR) | 2004-04-01 | — | — | WO | disclosed |
| US-5917090-A | INHIBIT TUMOR NECROSIS FACTOR; ANTIARTHRITIC AGENTS | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 1999-06-29 | — | — | US | disclosed |
| EP-0765876-B1 | Process for the preparation of (s)-beta-hydroxy-gamma-butyrolactone | SIGMA TAU IND FARMACEUTI (IT) | 1998-12-09 | — | — | EP | disclosed |
| US-5714619-A | Process for the preparation of (S)-β-hydroxy-γ-butyrolactone | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1998-02-03 | — | — | US | disclosed |
| EP-0765876-A1 | Process for the preparation of (s)-beta-hydroxy-gamma-butyrolactone | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1997-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093660-A1 | Method for the production of statins | HMGCR, CYP11A1, CYP51A1 | CYP2C19 121/4885HIF1A 402/4885TSHR 3911/4885 |
| US-20060052617-A1 | Continuous process for the production of optically pure (s)-beta-hydroxy-y-butyrolactone | HSD3B2, HSD3B1, HAO2 | CYP2C19 44/4885HIF1A 789/4885TSHR 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.